Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R
Cancer. 2002 95 (5): 1101-12

PMID: 12209697 · DOI:10.1002/cncr.10775

MeSH Terms (20)

Adult Aged Biomarkers, Tumor Chemotherapy, Adjuvant Female HLA Antigens Humans Intercellular Adhesion Molecule-1 Interferon-alpha Interferon alpha-2 Killer Cells, Natural Male Melanoma Middle Aged Phenotype Predictive Value of Tests Recombinant Proteins Skin Neoplasms T-Lymphocytes Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: